NASDAQ · Financial Statements

Kiniksa Pharmaceuticals International, plc (KNSA) Financial Statements

$76.73 NASDAQ: KNSA Market Cap $5.99B

Kiniksa Pharmaceuticals International, plc most recently reported annual revenue of $678.0M, net profit of $59.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Kiniksa Pharmaceuticals International, plc: net profit was positive in 3 of 10 reported years; operating margin moved from -406.4% to 11.4%, a shift of +417.8 percentage points; the most recent year shows net profit of $59.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$0$0$0$0$0$39.0M$220.0M$270.0M$423.0M$678.0M
Operating Expenses$24.0M$65.0M$108.0M$170.0M$157.0M$195.0M$210.0M$295.0M$469.0M$600.0M
Operating Profit$-24.0M$-65.0M$-108.0M$-170.0M$-157.0M$-157.0M$10.0M$-25.0M$-46.0M$77.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%-406.4%4.4%-9.3%-10.8%11.4%
Other Income$0$1.0M$5.0M$6.0M$1.0M$0$1.0M$9.0M$9.0M$12.0M
Interest$0$0$0$0$0$0$0$0$0$0
Depreciation$0$0$0$3.0M$4.0M$2.0M$2.0M$2.0M$2.0M$2.0M
Profit Before Tax$-24.0M$-65.0M$-103.0M$-164.0M$-156.0M$-157.0M$11.0M$-17.0M$-36.0M$89.0M
Tax$-150,000$0$210,000$1.3M$-3.3M$-880,000$-1.6B$184.6M$-19.5M$33.6M
Net Profit$-24.0M$-65.0M$-103.0M$-162.0M$-161.0M$-158.0M$183.0M$14.0M$-43.0M$59.0M
EPS$-0.74$-2.00$-3.49$-2.99$-2.61$-2.30$2.60$0.20$-0.60$0.75
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$67.0M$83.0M$80.0M$109.0M$112.0M$123.0M$138.0M$157.0M$181.0M$202.0M$214.0M$244.0M
Operating Expenses$78.0M$83.0M$96.0M$109.0M$122.0M$142.0M$125.0M$137.0M$157.0M$182.0M$185.0M$216.0M
Operating Profit$-11.0M$0$-17.0M$0$-10.0M$-19.0M$13.0M$20.0M$24.0M$20.0M$29.0M$27.0M
Operating Margin-16.3%0.1%-20.7%-0.1%-8.6%-15.8%9.6%12.9%13.3%9.8%13.7%11.2%
Interest$0$2.0M$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-8.0M$2.0M$-14.0M$2.0M$-7.0M$-17.0M$16.0M$23.0M$27.0M$23.0M$33.0M$31.0M
Tax$-63.0M$-930.1M$-24.0M$269.6M$-76.3M$47.6M$45.1M$22.1M$32.1M$39.0M$30.9M$18.3M
Net Profit$-14.0M$25.0M$-18.0M$-4.0M$-13.0M$-9.0M$9.0M$18.0M$18.0M$14.0M$23.0M$25.0M
EPS$-0.20$0.35$-0.25$-0.05$-0.18$-0.12$0.11$0.23$0.23$0.18$0.27$0.30

Over the 10 years reported for Kiniksa Pharmaceuticals International, plc, cash stood at $166.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 3.79 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$56.0M$47.0M$322.0M$255.0M$349.0M$233.0M$460.0M$526.0M$581.0M$764.0M
Current Assets$56.0M$47.0M$314.0M$242.0M$333.0M$196.0M$243.0M$276.0M$332.0M$527.0M
Cash$56.0M$46.0M$307.0M$47.0M$114.0M$122.0M$123.0M$108.0M$184.0M$166.0M
Inventory$0$0$0$0$0$4.0M$22.0M$31.0M$26.0M$55.0M
Receivables$0$0$0$0$0$4.0M$20.0M$21.0M$42.0M$16.0M
Fixed Assets$0$0$6.0M$8.0M$11.0M$8.0M$7.0M$13.0M$11.0M$12.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$186.0M$209.0M$60.0M$68.0M$98.0M$60.0M$248.0M
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$82.0M$137.0M$43.0M$29.0M$38.0M$48.0M$64.0M$87.0M$142.0M$196.0M
Current Liabilities$2.0M$17.0M$43.0M$28.0M$32.0M$45.0M$47.0M$64.0M$101.0M$139.0M
Borrowings$0$0$0$3.0M$7.0M$6.0M$6.0M$12.0M$10.0M$9.0M
Other Liabilities$82.0M$137.0M$43.0M$26.0M$31.0M$42.0M$58.0M$75.0M$132.0M$187.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$-26.0M$-90.0M$-194.0M$225.0M$312.0M$185.0M$396.0M$439.0M$438.0M$568.0M

For Kiniksa Pharmaceuticals International, plc, operating cash flow was positive in 4 of 10 reported years; free cash flow in the latest year was $25.0M; free cash flow was positive in 4 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$-22.0M$-50.0M$-81.0M$-158.0M$-137.0M$-126.0M$6.0M$13.0M$26.0M$26.0M
Investing Cash Flow$0$0$-478.0M$46.0M$-24.0M$108.0M$-8.0M$-30.0M$37.0M$37.0M
Financing Cash Flow$0$0$-3.0M$1.0M$-1.0M$0$-1.0M$1.0M$12.0M$12.0M
Net Cash Flow$21.0M$-10.0M$27.0M$-25.0M$67.0M$8.0M$0$-15.0M$76.0M$76.0M
Free Cash Flow$-22.0M$-50.0M$-86.0M$-162.0M$-137.0M$-147.0M$6.0M$13.0M$25.0M$25.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.04
EV / EBITDA50.04
FCF Yield3.17%
Quick Ratio3.49
Interest Coverage—
Return 1Y119.40%
Return 3Y361.01%
Return 5Y548.46%

Kiniksa Pharmaceuticals International, plc (KNSA) financials — frequently asked questions

What is Kiniksa Pharmaceuticals International, plc's annual revenue?

Kiniksa Pharmaceuticals International, plc (KNSA) reported annual revenue of $678.0M in its most recent fiscal year.

What is Kiniksa Pharmaceuticals International, plc's net profit?

Kiniksa Pharmaceuticals International, plc (KNSA) reported net profit of $59.0M in its most recent fiscal year.

What is KNSA EV/EBITDA?

Kiniksa Pharmaceuticals International, plc's enterprise value to EBITDA (EV/EBITDA) ratio is 50.04.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
KNSA Overview KNSA Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.